The calendar matters here. On July 1, 2026 — 26 days from today — the Medicare GLP-1 Bridge program launches, giving eligible Medicare beneficiaries access to Wegovy (semaglutide) injection and pill for a $50 monthly copay. For San Antonio, where an estimated 17% of Bexar County adults have diagnosed Type 2 diabetes — nearly double the national average of roughly 9% — and where approximately 72% of adults are overweight or obese compared to 42% nationally, this policy launch is among the most consequential healthcare access changes in the city's modern history. No city in America has more to gain from affordable GLP-1 access than San Antonio. And the countdown has now entered its final month.

To understand why July 1 matters so specifically for San Antonio residents, consider the populations it serves. The city's Medicare-covered population — principally adults 65 and older, plus disabled individuals of any age — numbers approximately 200,000 in Bexar County. Many of these residents have both obesity and cardiovascular disease or established heart disease. That combination is the exact clinical profile for which Novo Nordisk's Wegovy is FDA-approved under its cardiovascular indication — the SELECT cardiovascular outcomes trial found that semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with obesity and established heart disease. Heart disease is the leading cause of death in Bexar County. The $50 copay is a potential lifesaver for a population that currently pays $1,000+ per month out of pocket for brand-name injectable Wegovy.

The Policy Change That Congress Has Resisted for Decades

Medicare's historic ban on covering drugs prescribed purely for weight loss dates to 2003, when Congress created the Medicare Part D prescription drug benefit and specifically excluded "agents for anorexia or weight loss." The legislative intent was to prevent Medicare from covering expensive and marginally effective weight loss pills that were widely prescribed in the 1990s. The unintended consequence was that when GLP-1 drugs arrived — medications with documented efficacy vastly beyond anything the 2003 Congress imagined, with cardiovascular outcome data that changed what obesity treatment means — Medicare was legally prohibited from covering them for weight loss regardless of how strong the evidence was.

The Medicare GLP-1 Bridge program, announced by Novo Nordisk and organized through a Centers for Medicare and Medicaid Services demonstration program, partially circumvents this restriction through a combination of the cardiovascular indication (which Medicare already covers), the CMS BALANCE demonstration model, and manufacturer copay support. The full statutory prohibition is being addressed through Congressional action, but the Bridge program provides immediate access before that legislation is fully enacted. The program covers both injectable Wegovy and the oral Wegovy pill — the once-daily tablet launched in January 2026 at a $149 self-pay price — at the $50 monthly copay for eligible beneficiaries.

Read more

What San Antonio's Unique Disease Burden Means

San Antonio's diabetes and obesity statistics are not merely concerning — they are the product of specific, documented, interacting risk factors that make the city a microcosm of the GLP-1 revolution's potential and its challenges. The University Health Texas Diabetes Institute at University Health System — described as the nation's leading diabetes care and research center, located on the South Side of San Antonio where the disease burden is highest — has been at the forefront of documenting both the scale of the problem and the promise of GLP-1 solutions. Dr. Alberto Chavez-Velazquez, an endocrinologist at the Texas Diabetes Institute who was involved in early primate research on GLP-1 drugs, has stated that the medications "will essentially prevent the development of diabetes" in people with prediabetes and obesity.

That prediction has enormous implications for San Antonio's approximately 700,000 residents with prediabetes — a reversible metabolic condition that, without effective intervention, progresses to Type 2 diabetes in a significant fraction of cases. For those at risk, even a 50% reduction in progression rate would prevent hundreds of thousands of new diabetes diagnoses over the coming decade, with the downstream reduction in kidney failure, amputations, blindness, and cardiovascular deaths that diabetes currently causes every year in Bexar County. The American Cancer Society's 2026 research also confirmed a meaningful connection: GLP-1 use is now tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in non-diabetic women with elevated BMI — meaning the benefits of these drugs appear to extend even into cancer risk reduction.

Who Qualifies for the July 1 Medicare Coverage — and How to Apply

For the July 1 launch: Medicare Part D beneficiaries are eligible for Wegovy coverage through the Bridge program if they are prescribed Wegovy by their provider for an FDA-approved indication (cardiovascular risk reduction or weight management meeting BMI criteria) and meet clinical criteria for obesity treatment. Medicare Part D coverage also already covers GLP-1 drugs for Type 2 diabetes — so San Antonio residents with Medicare and diabetes should also discuss Ozempic or Mounjaro coverage with their provider if they are not already on these medications. The prior authorization process requires documentation of BMI and relevant comorbidities. San Antonio residents should schedule an appointment with their primary care provider now, before July 1, to initiate the prior authorization process so coverage is in place the day the Bridge launches. The Texas Diabetes Institute and University Health System's public health diabetes resources are available at universityhealth.com.